Ultragenyx Pharmaceutical Inc. (RARE) Scheduled to Post Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is set to release its earnings data after the market closes on Thursday, February 16th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.72) per share for the quarter.

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 76.24 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $46.52 and a 52-week high of $86.77. The stock’s 50 day moving average price is $72.27 and its 200-day moving average price is $70.41. The firm’s market cap is $3.12 billion.

“Ultragenyx Pharmaceutical Inc. (RARE) Scheduled to Post Quarterly Earnings on Thursday” was originally posted by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The original version of this report can be accessed at http://sleekmoney.com/ultragenyx-pharmaceutical-inc-rare-scheduled-to-post-quarterly-earnings-on-thursday/1661979.html.

Several equities analysts have recently issued reports on RARE shares. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $79.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 8th. Citigroup Inc. downgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “sell” rating and dropped their price target for the company from $66.00 to $64.00 in a research note on Monday, November 14th. Wedbush reaffirmed an “outperform” rating and set a $92.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 8th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $106.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $90.77.

In other news, Director William Aliski sold 6,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $78.19, for a total transaction of $469,140.00. Following the completion of the transaction, the director now directly owns 65,985 shares in the company, valued at $5,159,367.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.10% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/ultragenyx-pharmaceutical-inc-rare-scheduled-to-post-quarterly-earnings-on-thursday/1661979.html

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *